🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "significant breakthrough" in the effort against increasingly resistant strains of the bacteria, according to health experts.

A Global Health Concern

Cases of gonorrhoea are increasing worldwide, with estimates suggesting more than 82 million instances per year. Notably increased rates are reported in Africa and countries within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely step in the reality of increasing worldwide cases, escalating drug resistance and the extremely scarce treatment choices at this time.”

Health officials are deeply concerned about the increase in drug-resistant strains. The World Health Organization has listed it as a "critical concern". Recent surveillance found that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Receive Clearance

One new antibiotic, marketed under the name Nuzolvence, was cleared by the American regulatory agency in December for treating gonorrhoea. This disease can lead to serious health problems, including infertility. Experts anticipate that specific application of this new drug will help delay the development of resistance.

Gepotidacin, created by the drugmaker GSK, also received approval in concurrent days. This drug, which is also used to treat UTIs, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to bring it to fruition.

“This milestone marks a significant shift in the management of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Clinical Trial Outcomes and Worldwide Availability

Based on findings detailed in a major medical journal, zoliflodacin cured over nine in ten of uncomplicated infections. This puts it on an similar efficacy with the existing first-line therapy, which involves an injection and a pill. The research enrolled hundreds of volunteers from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, GARDP has the rights to make available and distribute the drug in numerous developing nations.

Medical professionals treating patients have voiced hope. The availability of a single-dose, oral treatment like this is seen as a "critical tool" for managing the epidemic. This is viewed as essential to lessen the impact of the illness for individuals and to halt the transmission of highly drug-resistant gonorrhoea globally.